Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Pay, Patriots And The Art of Promise: What Results Season Taught Us

Most of the biggest pharmaceutical companies that pay taxes in Europe or North America have told the world how they got on in 2017. So what, other than the corrective value of financial performance minutiae, did we learn?

Business Strategies Biosimilars Commercial

Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate

In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.

Cardiovascular Research & Development Market Intelligence

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
ImmunoOncology Cancer Approvals

Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

The big-selling psoriasis drug has achieved healthy clinical remission rates in a Phase II trial for ulcerative colitis, and Celgene believes Otezla and another potential blockbuster, ozanimod, will help it build a significant presence in inflammatory bowel disease.

Gastrointestinal Clinical Trials Research & Development
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal

Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.

Rare Diseases Deals Respiratory

BiomX Wants To Reverse The Focus Of Microbiome Therapy

Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.

StartUps and SMEs Platform Technologies Gastrointestinal

Strides' Net Profit Dives But Regulated Markets Seen Delivering Growth

Strides Shasun has reported third-quarter net profit plunged by 57% but the Indian firm says performance will improve in coming quarters thanks to its regulated market focus, and analysts agree earnings look set to rise.
Commercial Companies

Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset

Sun Pharma reported a sharp decline in Q3 profits, dented by tax adjustments related to changes in US tax rates and continuing pricing pressures there. With Q4 revenues expected to to be "similar” to Q3, all eyes are on the Halol site making the compliance cut and the upcoming PDUFA date for Sun’s psoriasis asset.

Commercial Companies

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Business Strategies Commercial

Celltrion's Trastuzumab Biosimilar Gets EC Nod

With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.

Commercial Approvals

Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.
Sales & Earnings Business Strategies

Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation

Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.

Human Capital Leadership

Policy & Regulation Explore this Topic

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
ImmunoOncology Cancer Approvals

FDA Deputy On CRLs: 'It's Not Our Property To Release'

US FDA Principal Deputy Commissioner Rachel Sherman said during the BIO CEO & Investor conference that while investors and others would like to see complete response letters, the agency's hands are bound when it comes to their full release. Sherman also commented on FDA's focus for right-to-try legislation.

FDA Complete Response Letters

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

J&J subsidiary Janssen's Erleada (apalutamide) is the first therapy approved for non-metastatic castration-resistant prostate cancer (nmCRPC). The US FDA decision came about two months early, but the drug – priced at $10,920 per month, or $131,040 annually – may soon face competition.
Approvals Cancer

Bayer In FDA's Bad Books Over Facility Failures

Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling  products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.

Manufacturing FDA

Research & Development Explore this Topic

Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals Research & Development

Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer

The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
Clinical Trials ImmunoOncology

Interview: Ferring Forges Ahead With mAbs For Reproductive Meds

Antibody-based therapies have not really been investigated in the area of reproductive medicine and women’s health but Ferring is investing heavily to explore their potential, head of global pharmaceutical R&D Armin Metzger tells Scrip.

Biologics Gynecology & Urology

Biogen Spooks With Phase III Aducanumab Changes

Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational Alzheimer's therapies, the difficulty in maintaining confidence in the development of new therapies for the condition has been underlined by investor responses to Biogen's alterations.

Neurology Clinical Trials
UsernamePublicRestriction

Register

Advertisement